Various biotech companies have completed or launched their IPOs so far in 2025. As of early February, five sizeable life sciences companies have priced their IPOs and one has filed to go public soon. The after-market performance of priced IPOs has been mixed so far. We expect the rest of February to be slow, which is typical, due to audited financial statement requirements.
Based on the pipeline of companies we see working on their IPOs, 2025 currently looks like it may be more promising than 2024. Planning for and executing on an IPO takes many months and extreme focus by a company's C-suite and board. Before they can take advantage of a favorable IPO window, companies typically need to disclose impressive clinical trial data in their SEC filings, build out their management and finance department capabilities, prepare audited financial statements, have strong inside investor support, and put in place a strong governance infrastructure. Read more about the key elements of IPO preparation and watch our webinar.
For life sciences companies considering an IPO in 2025, now is the time to begin preparations. While market conditions appear promising, success requires careful planning and execution across multiple workstreams. Companies should focus on building strong foundational elements while maintaining flexibility to take advantage of market windows when they arise.
www.fenwick.com/...
